NCT03065309

Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Brasilia University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension

Detailed description

Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life. Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.

Conditions

• Bradycardia
• Hypotension

Interventions

Type	Name	Description
DRUG	Remifentanil	bolus dose

Timeline

• Start date: 2017-02-25
• Primary completion: 2017-02-28
• Completion: 2017-03-01
• First posted: 2017-02-27
• Last updated: 2017-09-13

Locations

1 site across 1 country: Brazil